Glutamate is the brain's main excitatory neurotransmitter. Glutamatergic neurons primarily
compose basic neuronal networks, especially in the cortex. An imbalance of excitatory and …

Drug-resistant epilepsy occurs in 25–30% of patients. Furthermore, treatment with a first-
generation antiseizure drug (ASD) fails in 30–40% of individuals because of their intolerable …

bstract Introduction NGLY1-associated congenital disorder of deglycosylation (CDDG1:
OMIM# 615273) is a rare autosomal recessive disorder caused by a functional impairment of …

Objective The temporal lobe plays a central role in the regulation of the" Central Autonomic
Network" and cardiovascular functions. The blockade of glutamatergic pathways in the …

Genetic factors contribute to the aetiology of epilepsy in> 50% of cases, and information on
the use of antiseizure medications in people with specific aetiologies will help guide …

Abstract Progressive Myoclonus Epilepsy (PME) is a rare epilepsy syndrome characterized
by the development of progressively worsening myoclonus, ataxia, and seizures. A …

Introduction Drug management of epilepsy in the elderly presents unique but data on this
population are scarce. This study aimed to assess the effectiveness and tolerability of …

The progressive myoclonus epilepsies (PME) are a diverse group of disorders that feature
both myoclonus and seizures that worsen gradually over a variable timeframe. While each of …

Introduction The late onset myoclonic epilepsy in Down Syndrome (LOMEDS) is a peculiar
epilepsy type characterized by cortical myoclonus and generalized tonic-clonic seizures …

Lafora disease is a rare genetic disorder characterized by a disruption in glycogen
metabolism. It manifests as progressive myoclonus epilepsy and cognitive decline during …